GSK plc (LON:GSK) Given Average Rating of “Moderate Buy” by Brokerages

Shares of GSK plc (LON:GSK) have earned a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is GBX 1,805.83 ($22.48).

GSK has been the topic of a number of research reports. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a research note on Tuesday, January 7th. Berenberg Bank lowered their price objective on GSK from GBX 1,820 ($22.65) to GBX 1,600 ($19.92) and set a “buy” rating on the stock in a research note on Friday, November 29th.

Insider Buying and Selling at GSK

In related news, insider Jonathan Symonds bought 1,500 shares of GSK stock in a transaction on Friday, December 20th. The stock was acquired at an average price of GBX 1,315 ($16.37) per share, with a total value of £19,725 ($24,551.90). Also, insider Emma Walmsley sold 120,653 shares of GSK stock in a transaction dated Monday, February 10th. The shares were sold at an average price of GBX 1,453 ($18.09), for a total value of £1,753,088.09 ($2,182,086.25). Insiders own 1.61% of the company’s stock.

GSK Trading Down 0.8 %

LON GSK opened at GBX 1,434 ($17.85) on Friday. The stock has a market capitalization of £58.51 billion, a price-to-earnings ratio of 1,269.03, a PEG ratio of 1.24 and a beta of 0.31. GSK has a one year low of GBX 1,282.50 ($15.96) and a one year high of GBX 1,823.50 ($22.70). The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73. The business’s fifty day moving average is GBX 1,363.57 and its 200-day moving average is GBX 1,455.91.

GSK (LON:GSK) last released its earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) EPS for the quarter. GSK had a return on equity of 33.30% and a net margin of 12.83%. Equities research analysts predict that GSK will post 175.980975 EPS for the current year.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.